newsfilter
← Latest News
GlobeNewswire·

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company's Alzheimer's Disease clinical trial results NEW YORK, Nov. 14,